Astrazeneca — ASCO 2018 Annual Meeting

5 slides from Astrazeneca's conference presentation, Jun 1, 2018

Slide 1: Taking our science to the ASCO 2018 Annual Meeting
Taking our science to the ASCO 2018 Annual Meeting Investor and analyst planner and information pack Chicago, Illinois, USA 01 June 2018
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, pe
Slide 3: Key AstraZeneca abstracts
Key AstraZeneca abstracts Date Time Abstract # Title Friday 1 June 14:45 2503 Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway 16:30 6011 Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squa
Slide 4: Investor event 4 June 2018
Investor event 4 June 2018 Location Hyatt Regency 151 East Wacker Drive, Chicago, Illinois 60601, USA Agenda (CDT) 18:30 Light food and drinks 19:15 Investor event 21:00 Post-event drinks 4
Slide 5: AstraZeneca IR Team members at ASCO 2018
AstraZeneca IR Team members at ASCO 2018 Thomas Kudsk Larsen Christer Gruvris thomas.larsen@astrazeneca.com christer.gruvris@astrazeneca.com +44 7818 524185 +44 7827 836825 Mitchell Chan Nick Stone mitchell.chan@astrazeneca.com nick.stone@astrazeneca.com +1 240 477 3771 +44 7717 618834 Henry Wheeler